Skip to main content

Advertisement

SpringerLink
Log in

The effect of first dose of tamsulosin on flow rate and its predictive ability on the improvement of LUTS in men with BPH in the mid-term

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

To investigate if effects of the first single dose of tamsulosin 0.4 mg on uroflowmetry parameters would predict treatment response at the third month.

Methods

Men over 40 years old with complaints of lower urinary tract symptoms associated with benign prostatic hyperplasia were studied with physical examination, urine and blood analysis, uroflowmetry (UFM), post-voiding residual urine volume (PVR), international prostate symptom score (IPSS), quality-of-life (QoL) index and transrectal prostate ultrasonography (TRUS), and patients with prostate cancer suspicion, past urinary surgery, urinary tract infection and neurologic diseases were excluded. UFM, PVR, IPSS, QoL were repeated at 6th hour of the first day, first month and third month of oral tamsulosin 0.4 mg treatment. All parameters were recorded as baseline, and changes in the UFM parameters, PVR, IPSS and QoL were evaluated in clinical visits.

Results

As a total, 48 men (mean 60.17 ± 1.18 years) were recruited. There was a significant increase in maximum urine flow rate (Q max) and average urine flow rate (Q ave) and decrease in PVR from baseline with the first dose of tamsulosin as well as first and third month of treatment (p < 0.05). IPSS and QoL scores significantly improved at the first month in correlation with UFM parameters. Tamsulosin treatment was effective in 33 (68.7 %) patients at the first administration and 35 (72.9 %) at the third month. Positive predictive value and negative predictive value of Q max change at first dose for the third month response rate were 90.9 and 66.6 %, respectively.

Conclusions

The mid-term effectiveness of tamsulosin may be predicted by changes in UFM parameters achieved with its first dose.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, Lieber MM (1993) The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 150:85–89

    PubMed  CAS  Google Scholar 

  2. Gai M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M (2012) A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 61:994–1003

    Article  Google Scholar 

  3. Chen Y, Zhang X, Hu X, Deng Y, Chen J, Li S, Zhang C, Wang J, Liu Z, Hao Y, Xiao Y, Yuan J, Xu T, Wang X (2012) The potential role of a self-management intervention for benign prostate hyperplasia. Urology 79:1385–1388

    Article  PubMed  Google Scholar 

  4. Shrivastava A, Gupta VB (2012) Various treatment options for benign prostatic hyperplasia: a current update. J Midlife Health 3:10–19

    PubMed  Google Scholar 

  5. Buzelin JM, Fonteyne E, Kontturi M, Witjes WP, Khan A (1997) Comparison of tamsulosin hydrochloride with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic obstruction). BJU Int 80:597–605

    Article  CAS  Google Scholar 

  6. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46:547–554

    Article  PubMed  Google Scholar 

  7. Chapple CR (1998) Pharmacotherapy for benign prostatic hyperplasia the potential for alpha 1-adrenoceptor subtype-specific blockade. Br J Urol 81(Suppl 1):34–47

    PubMed  CAS  Google Scholar 

  8. Lepor H (2007) Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol 9:181–190

    PubMed  Google Scholar 

  9. Muruganandham K, Dubey D, Kapoor R (2007) Acute urinary retention in benign prostatic hyperplasia: risk factors and current management. Indian J Urol 23:347–353

    Article  PubMed  CAS  Google Scholar 

  10. McNeill SA, Daruwala PD, Mitchell ID, Shearer MG, Hargreave TB (1999) Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled. BJU Int 84:622–627

    Article  PubMed  CAS  Google Scholar 

  11. Chapple CR (2005) A comparison of varying alpha-blockers and other pharmacotherapy options for lower urinary tract symptoms. Rev Urol 7(Suppl 4):22–30

    Google Scholar 

  12. Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474–479

    PubMed  CAS  Google Scholar 

  13. Irani J (2006) Are all alpha-blockers created the same? Eur Urol 49:420–422

    Article  PubMed  Google Scholar 

  14. Roehrborn CG, Schwinn DA (2004) Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 171:1029–1035

    Article  PubMed  CAS  Google Scholar 

  15. Narayan P, Evans CP, Moon T (2003) Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 170:498–502

    Article  PubMed  Google Scholar 

  16. Narayan P, Lepor H (2001) Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 57:466–470

    Article  PubMed  CAS  Google Scholar 

  17. Michel MC, Mehlburger L, Bressel HU, Goepel M (1998) Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prost Dis 1:332–335

    Article  CAS  Google Scholar 

  18. Michel MC, de la Rosette JJ (2004) Efficacy and safety of tamsulosin in the treatment of urological diseases. Expert Opin Pharmacother 5:151–160

    Article  PubMed  CAS  Google Scholar 

  19. Korstanje C, Krauwinkel W, van Doesum-Wolters FL (2011) Tamsulosin shows a higher unbound drug fraction in human prostate than in plasma: a basis for uroselectivity? Br J Clin Pharmacol 72:218–225

    Article  PubMed  CAS  Google Scholar 

  20. Wolzt M, Fabrizii V, Dorner GT, Zanaschka G, Leufkens P, Krauwinkel WJ, Eichler HG (1998) Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single dose and multiple-dose study. Eur J Clin Pharmacol 54:367–373

    Article  PubMed  CAS  Google Scholar 

  21. Michel MC, Büscher R, Kerker J, Kraneis H, Erdbrügger W, Brodde OE (1993) A1-adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Naunyn Schmiedebergs Arch Pharmacol 348:385–395

    PubMed  CAS  Google Scholar 

  22. Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G (1995) Use of recombinant a1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 288:201–207

    Article  PubMed  CAS  Google Scholar 

  23. Lyseng-Williamson KA, Jarvis B, Wagstaff AJ (2002) Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs 62:135–167

    Article  PubMed  CAS  Google Scholar 

  24. Soeishi Y, Matsushima H, Watanabe T, Higuchi S, Cornelissen K, Ward J (1996) Absorption, metabolism and excretion of tamsulosin hydrochloride in man. Xenobiotica 26:637–645

    Article  PubMed  CAS  Google Scholar 

  25. Chung JW, Choi SH, Kim BS, Kim TH, Yoo ES, Kim CI, Lee KS, Kwon TG (2011) Efficacy and tolerability of tamsulosin 0.4 mg in patients with symptomatic benign prostatic hyperplasia. Korean J Urol 52:479–484

    Article  PubMed  Google Scholar 

  26. Chang HS, Park CH, Kim DK, Park JK, Hong SJ, Chung BH, Lee JG, Kim CS, Lee KS, Kim JC (2010) Assessment of patient-reported outcome of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and treated with tamsulosin HCl in Korea. Urology 75:1156–1161

    Article  PubMed  Google Scholar 

  27. Kang SG, Park CH, Kim DK, Park JK, Hong SJ, Chung BH, Kim CS, Lee KS, Kim JC, Lee JG (2011) Long-term outcome of tamsulosin for patients with lower urinary tract symptoms according to the treatment response defined by lower urinary tract symptom outcomes score. Int J Clin Pract 65:691–697

    Article  PubMed  CAS  Google Scholar 

  28. Djavan B, Chapple C, Milani S, Marberger M (2004) State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 64:1081–1088

    Article  PubMed  Google Scholar 

  29. Schwin DA (2001) The role of alpha 1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 88:27–34

    Article  Google Scholar 

  30. Park CH, Chang HS, Oh BR et al (2004) Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Clin Drug Investig 24:41–47

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This project has been supported by Akdeniz University Scientific Research and Project Units.

Conflict of interest

The authors have no conflict of interests.

Author information

Authors and Affiliations

  1. Department of Urology, Erzincan University School of Medicine, 24040, Erzincan, Turkey

    Yigit Akin

  2. Department of Family Medicine, Baskent University School of Medicine, 06600, Ankara, Turkey

    Hakan Gulmez

  3. Department of Urology, Akdeniz University School of Medicine, 07059, Antalya, Turkey

    Yigit Akin, Murat Ucar & Selcuk Yucel

Authors
  1. Yigit Akin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hakan Gulmez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Murat Ucar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Selcuk Yucel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Selcuk Yucel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Akin, Y., Gulmez, H., Ucar, M. et al. The effect of first dose of tamsulosin on flow rate and its predictive ability on the improvement of LUTS in men with BPH in the mid-term. Int Urol Nephrol 45, 45–51 (2013). https://doi.org/10.1007/s11255-012-0377-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-012-0377-8

Keywords

Search

Navigation